106 related articles for article (PubMed ID: 38400797)
1. Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction-associated steatotic liver disease.
Tamaki N; Wakabayashi SI; Kimura T; Yasui Y; Tsuchiya K; Nakanishi H; Huang DQ; Umemura T; Kurosaki M; Izumi N
Hepatol Res; 2024 Feb; ():. PubMed ID: 38400797
[TBL] [Abstract][Full Text] [Related]
2. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.
Tamaki N; Kimura T; Wakabayashi SI; Umemura T; Kurosaki M; Loomba R; Izumi N
Aliment Pharmacol Ther; 2024 Jul; 60(1):61-69. PubMed ID: 38664876
[TBL] [Abstract][Full Text] [Related]
3. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
4. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study.
Moon JH; Jeong S; Jang H; Koo BK; Kim W
EClinicalMedicine; 2023 Nov; 65():102292. PubMed ID: 37954905
[TBL] [Abstract][Full Text] [Related]
5. The prognostic effect of prediabetes defined by different criteria in patients with stable coronary artery disease: a prospective cohort study in Asia.
Cui K; Yin D; Song W; Wang H; Zhu C; Feng L; Li J; Jia L; Lu Y; Zhang R; Shi B; Song Y; Fu R; Dou K
Eur J Prev Cardiol; 2023 Oct; 30(14):1418-1426. PubMed ID: 36987575
[TBL] [Abstract][Full Text] [Related]
6. Cause-specific risk of major adverse cardiovascular outcomes and hypoglycemic in patients with type 2 diabetes: a multicenter prospective cohort study.
Sun B; He F; Sun L; Zhou J; Shen J; Xu J; Wu B; Liu R; Wang X; Xu H; Chen X; Zhou H; Liu Z; Zhang W
Endocrine; 2019 Jan; 63(1):44-51. PubMed ID: 30121774
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Dysfunction Associated Liver Disease in Patients Undergoing Coronary Computed Tomography Angiography.
Orzan RI; Gligor RI; Agoston R; Cionca C; Zlibut A; Pais R; Seicean A; Agoston-Coldea L
J Cardiovasc Dev Dis; 2024 Feb; 11(3):. PubMed ID: 38535100
[TBL] [Abstract][Full Text] [Related]
8. Combined effect of histological findings and diabetes mellitus on liver-related events in patients with metabolic dysfunction-associated steatotic liver disease.
Shiomi A; Miyake T; Furukawa S; Matsuura B; Yoshida O; Watanabe T; Kanamoto A; Miyazaki M; Nakaguchi H; Tokumoto Y; Hirooka M; Abe M; Hiasa Y
Hepatol Res; 2024 Apr; ():. PubMed ID: 38656764
[TBL] [Abstract][Full Text] [Related]
9. Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study.
Lin M; Gao B; Peng M; Chen X; Xiao H; Shi M; Zhang X; Zeng F; Chi X
Front Physiol; 2024; 15():1347459. PubMed ID: 38405121
[No Abstract] [Full Text] [Related]
10. Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and the risk of hepatocellular carcinoma: a nationwide cohort study.
Jeong S; Oh YH; Ahn JC; Choi S; Park SJ; Kim HJ; Lee G; Son JS; Jang H; Lee DH; Sha M; Chen L; Kim W; Park SM
Clin Mol Hepatol; 2024 May; ():. PubMed ID: 38711390
[TBL] [Abstract][Full Text] [Related]
11. HbA1c is a predictive factor of severe coronary stenosis and major adverse cardiovascular events in patients with both type 2 diabetes and coronary heart disease.
Jiao X; Zhang Q; Peng P; Shen Y
Diabetol Metab Syndr; 2023 Mar; 15(1):50. PubMed ID: 36935502
[TBL] [Abstract][Full Text] [Related]
12. Association Between Hemoglobin A1c and Major Adverse Coronary Events in Patients with Diabetes Following Coronary Artery Bypass Surgery.
Turgeon RD; Koshman SL; Youngson E; Pearson GJ
Pharmacotherapy; 2020 Feb; 40(2):116-124. PubMed ID: 31883378
[TBL] [Abstract][Full Text] [Related]
13. Effect of baseline glycemic level on long-term cardiovascular outcomes after coronary revascularization therapy in patients with type 2 diabetes mellitus treated with hypoglycemic agents.
Ehara N; Morimoto T; Furukawa Y; Shizuta S; Taniguchi R; Nakagawa Y; Hoshino K; Saito N; Doi T; Haruna Y; Ozasa N; Imai Y; Teramukai S; Fukushima M; Kita T; Kimura T
Am J Cardiol; 2010 Apr; 105(7):960-6. PubMed ID: 20346313
[TBL] [Abstract][Full Text] [Related]
14. Glycemic Control in Type 1 Diabetes and Long-Term Risk of Cardiovascular Events or Death After Coronary Artery Bypass Grafting.
Nyström T; Holzmann MJ; Eliasson B; Kuhl J; Sartipy U
J Am Coll Cardiol; 2015 Aug; 66(5):535-43. PubMed ID: 26227192
[TBL] [Abstract][Full Text] [Related]
15. Impact of HIV Infection on Liver and Cardiovascular Outcomes in Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease.
Wong RJ; Yang Z; Yeoh A; Do A; Ahmed A; Cheung R
Am J Gastroenterol; 2024 Apr; ():. PubMed ID: 38477465
[TBL] [Abstract][Full Text] [Related]
16. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
[TBL] [Abstract][Full Text] [Related]
17. Clinical influence of early follow-up glycosylated hemoglobin levels on cardiovascular outcomes in diabetic patients with ST-segment elevation myocardial infarction after coronary reperfusion.
Ahn J; Hong TJ; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Cha KS; Yun E; Jeong MH; Chae SC; Kim YJ; Hur SH; Seong IW; Jang YS; Cho MC; Kim CJ; Seung KB; Rha SW; Bae JH; Park SJ;
Coron Artery Dis; 2015 Nov; 26(7):555-61. PubMed ID: 25933028
[TBL] [Abstract][Full Text] [Related]
18. HbA1c, Coronary atheroma progression and cardiovascular outcomes.
Dykun I; Bayturan O; Carlo J; Nissen SE; Kapadia SR; Tuzcu EM; Nicholls SJ; Puri R
Am J Prev Cardiol; 2022 Mar; 9():100317. PubMed ID: 35112095
[TBL] [Abstract][Full Text] [Related]
19. Metabolic dysfunction-associated steatotic liver disease and risk of esophageal cancer in patients with diabetes mellitus: a nationwide cohort study.
Jeon YJ; Han K; Lee SW; Lee JE; Park J; Cho IY; Cho JH; Shin DW
Dis Esophagus; 2024 Apr; ():. PubMed ID: 38587429
[TBL] [Abstract][Full Text] [Related]
20. Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease.
Mak AL; Wassenaar N; van Dijk AM; Troelstra M; Houttu V; van Son K; Driessen S; Zwirs D; van den Berg-Faay S; Shumbayawonda E; Runge J; Doukas M; Verheij J; Beuers U; Nieuwdorp M; Cahen DL; Nederveen A; Gurney-Champion O; Holleboom A
JHEP Rep; 2024 Mar; 6(3):100998. PubMed ID: 38379586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
